Skip to main content
  • Home
  • Optimising Treatment of HF

Optimising Treatment of HF

Topic:
  • CV Renal Metabolic
  • Heart Failure

Available Credit:

  • 1.00 (EBAC)

Course Published On:

Course Expiry Date:

Overview

Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.

 

Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

Course Instructions

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within the suggested timelines and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim credit participants must:

1. Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.

2. Your results will be automatically saved and if a pass score is achieved, you may be eligible to claim credit for the activity and receive a certificate of completion.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • Nurses
  • Allied Health Professionals

Learning Objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
Register now Log in

Module

Title

Duration

Speakers

1 Introduction – Optimising Treatment of HF Martin R Cowie (Royal Brompton Hospital, London, UK)
2 A Review of Recent SGLT2 Inhibitor Data Giuseppe Rosano (University of London, London, UK)
3 New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor? Javed Butler (Jackson, Mississippi, US)
4 Existing HF-REF: Augmenting the SOC Shelley Zieroth (University of Manitoba, Canada)
5 How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF? Martin R Cowie (Royal Brompton Hospital, London, UK) Javed Butler (Jackson, Mississippi, US) Shelley Zieroth (University of Manitoba, Canada) Giuseppe Rosano (University of London, London, UK)
1.

Introduction – Optimising Treatment of HF

Duration:

Speakers: Martin R Cowie (Royal Brompton Hospital, London, UK)

2.

A Review of Recent SGLT2 Inhibitor Data

Duration:

Speakers: Giuseppe Rosano (University of London, London, UK)

3.

New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

Duration:

Speakers: Javed Butler (Jackson, Mississippi, US)

4.

Existing HF-REF: Augmenting the SOC

Duration:

Speakers: Shelley Zieroth (University of Manitoba, Canada)

Speaker

Martin R Cowie

Imperial College London, and Royal Brompton Hospital, London, UK

Dr Martin R Cowie is Professor of Cardiology at King's College London and Honorary Consultant Cardiologist at the Royal Brompton Hospital, London.

View full profile

Javed Butler

University of Mississippi Medical Center, Jackson, MS, US

Javed Butler, MD, MPH, MBA, is the Patrick H Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson, Mississippi. He is also Professor of Physiology.

View full profile

Giuseppe Rosano

St George’s University Medical School of London, UK

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London where he is also the director of MSc Heart Failure. 

View full profile

Shelley Zieroth

Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, CA

Dr Shelley Zieroth is currently at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

View full profile

The programme ‘Optimising Treatment of HF’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Renal Denervation In The Real World: Practical Guidance For New Users
  • 1 EBAC

Learning objectives

  • Assess the current global burden of resistant hypertension
  • Carry out appropriate assessments to identify resistant hypertension
  • Identify patients most likely to benefit from RDN
  • Recall the practical considerations for adopting RDN into routine practice
  • Recall the latest data on RDN from recent clinical trials
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Renal Denervation in Patients with Treatment-resistant Hypertension
  • 1.00 EBAC

Learning objectives

  • Describe the evidence to support the use of renal denervation as a treatment modality in patients with resistant hypertension
  • Understand renal denervation and how effective it is as a treatment option
  • Identify patients with resistant hypertension suitable for renal denervation
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Heart Failure & Cardiomyopathy: Highlights 2019-2021
  • 0.25 AMA PRA Category 1 Credit™

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
See more